Paper - WANFANG MED ONLINE

You Position: Home > Paper

程序性死亡受体与程序性死亡配体1在肿瘤免疫治疗中的进展

( views:75, downloads:256 )

Author:: No author available

Journal Title:: China Clinical Practical Medicine

Issue:: 2

DOI:: 10.3760/cma.j.issn.1673-8799.2018.02.021

Key Word:: 程序性死亡受体;程序性死亡配体1;T细胞;肿瘤;免疫治疗

Abstract：由于全球人口增长、老龄化日益加剧及持续存在的不健康的生活方式,肿瘤的发病率越来越高,已成为严峻社会的负担.目前,肿瘤的治疗方式有外科手术治疗、化学治疗、放射治疗、靶向治疗和免疫治疗等.由于晚期患者的手术效果受限且传统化学治疗的不良反应较为明显,近年来出现的免疫治疗逐渐引起重视.肿瘤免疫治疗包括免疫调节剂(非特异性)、过继性免疫治疗(被动免疫)、肿瘤疫苗(主动免疫)及免疫检查点阻断治疗.目前,免疫检查点阻断治疗是肿瘤治疗研究的热点,如针对细胞毒性T淋巴细胞相关抗原4(CTLA-4)的治疗,针对T细胞程序性死亡受体(PD-1)及程序性死亡配体1(PD-L1)的治疗等.抗PD-1及其配体PD-L1的相关药物,在多种肿瘤的治疗中显示出较好的治疗效果.现对PD-1、PD-L1在肿瘤免疫治疗中的进展作一综述.

Reference

[1]Tengfei, Zhang,Jing, Xie,Seiji, Arai,etc.The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.[J].2016,(45).
[2]Duraiswamy,J.,Kaluza,K.M.,Freeman,G.J.,etc.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors[J].2013,73(12).
[3]Wigginton,J.M.,Brahmer,J.R.,McDonald,D.,etc.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J].2012,366(26).
[4]Douglas B, Johnson,Erika K, Wallender,Daniel N, Cohen,etc.Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.[J].2013,1(6).
[5]Sonpavde, Guru.PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma[J].2017,376(11).
[6]Ohaegbulam, Kim C.,Assal, Amer,Lazar-Molnar, Eszter,etc.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].2015,21(1).
[7]Camille Mazza,Bernard Escudier,Laurence Albiges.Nivolumab in renal cell carcinoma: latest evidence and clinical potential[J].2017,9(3).
[8]Hartkopf, Andreas D.,Taran, Florin-Andrei,Wallwiener, Markus,etc.PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer[J].2016,11(6).
[9]Pai‐Scherf Lee,Blumenthal Gideon M.,Li Hongshan,etc.FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond[J].2017,22(11).
[10]Ott, Patrick A.,Elez, Elena,Hiret, Sandrine,etc.Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study[J].2017,35(34).
[11]Y, Ishida,Y, Agata,K, Shibahara,etc.Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.[J].1992,11(11).
[12]Calderaro, Julien,Rousseau, Benoit,Amaddeo, Giuliana,etc.Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features[J].2016,64(6).
[13].Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.[J].2017,49(1).
[14]Pin, Wu,Dang, Wu,Lijun, Li,etc.PD-L1 and Survival in Solid Tumors: A Meta-Analysis.[J].2015,10(6).
[15]De Velasco, Guillermo,Je, Youjin,Bosse, Dominick,etc.Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients[J].2017,5(4).
[16]Hitomi, Mori,Makoto, Kubo,Rin, Yamaguchi,etc.The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.[J].2017,8(9).
[17]Daud, Adil I.,Wolchok, Jedd D.,Robert, Caroline,etc.Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma[J].2016,34(34).
[18]Nishijima, Tomohiro F.,Shachar, Shlomit S.,Nyrop, Kirsten A.,etc.Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis[J].2017,22(4).
[19]Boussiotis, Vassiliki A..Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway[J].2016,375(18).
[20]Moreno, B. Homet,Ribas, A..Anti-programmed cell death protein-1/ligand-1 therapy in different cancers[J].2015,112(9).
[21]Torre, Lindsey A.,Bray, Freddie,Siegel, Rebecca L.,etc.Global Cancer Statistics, 2012[J].2015,65(2).
[22]Melani, Christopher,Major, Ajay,Wilson, Wyndham H.,etc.PD-1 Blockade in Mediastinal Gray-Zone Lymphoma[J].2017,377(1).
[23]Herbst, Roy S.,Soria, Jean-Charles,Kowanetz, Marcin,etc.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].2014,515(Nov.27 TN.7528).
[24]Ribas, Antoni,Shin, Daniel Sanghoon,Zaretsky, Jesse,etc.PD-1 Blockade Expands Intratumoral Memory T Cells[J].2016,4(3).
[25]Lorenz, Hanns-Martin,Hassel, Jessica C.,Benesova, Karolina,etc.Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies[J].2018,67(2).
[26]Jonasch Eric,Kawakami Fumi,Sircar Kanishka,etc.Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation[J].2017,123(24).
[27]Kelderman, Sander,Schumacher, Ton N.,Kvistborg, Pia.Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy[J].2015,28(1).
[28]Hoos A,Shahabi V,Canetta R,etc.Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.[J].2010,37(5).
[29]Raanan, Berger,Rinat, Rotem-Yehudar,Gideon, Slama,etc.Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.[J].2008,14(10).
[30]Mir, Olivier,Honore, Charles,Adam, Julien.PD-1 inhibition in bone sarcoma and soft-tissue sarcoma[J].2017,18(11).
[31]Renaud, Sabatier,Pascal, Finetti,Emilie, Mamessier,etc.Prognostic and predictive value of PDL1 expression in breast cancer.[J].2015,6(7).
[32]Botti, Gerardo,Collina, Francesca,Scognamiglio, Giosu��,etc.Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.[J].2017,18(2).
[33]Sclafani, Francesco.PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer[J].2017,18(9).
[34]Xiaohui Zhang,Yuanyuan Zeng,Qiuxia Qu,etc.PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer[J].2017,22(6).
[35]Calpe-Armero, Pablo,Perez-Pitarch, Alejandro,Ferriols-Lisart, Francisco,etc.Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice[J].2017,62(6).
[36]Mahoney, Kathleen M.,Freeman, Gordon J.,McDermott, David F..The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma[J].2015,37(4).
[37]Okita, Riki,Maeda, Ai,Shimizu, Katsuhiko,etc.PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer[J].2017,66(7).